BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 21116113)

  • 21. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
    Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
    Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
    Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
    Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical detection of epidermal growth factor receptor lacks prognostic significance for breast carcinoma.
    Göhring UJ; Ahr A; Scharl A; Weisner V; Neuhaus W; Crombach G; Holt JA
    J Soc Gynecol Investig; 1995; 2(4):653-9. PubMed ID: 9420872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
    Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
    Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas.
    Gursan N; Karakök M; Sari I; Gursan MS
    Int J Clin Pract; 2001 Nov; 55(9):589-90. PubMed ID: 11770353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metallothionein expression in invasive and in situ breast carcinomas.
    Gallicchio LM; Flaws JA; Fowler BA; Ioffe OB
    Cancer Detect Prev; 2005; 29(4):332-7. PubMed ID: 16122884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance.
    Michels JJ; Duigou F; Marnay J; Henry-Amar M; Delozier T; Denoux Y; Chasle J
    Cancer; 2003 Mar; 97(6):1376-86. PubMed ID: 12627500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma.
    Acs G; Esposito NN; Rakosy Z; Laronga C; Zhang PJ
    Am J Surg Pathol; 2010 Nov; 34(11):1637-46. PubMed ID: 20975342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components.
    Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ
    J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Expression and significance of TRAF4 protein in breast carcinoma].
    Dai WB; Zheng YW; Mi XY; Liu N; Lin H; Yan J
    Ai Zheng; 2007 Oct; 26(10):1095-8. PubMed ID: 17927880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breast carcinoma in women 35 years and younger: a pathological study.
    Fernandopulle SM; Cher-Siangang P; Tan PH
    Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
    Zhang R; Zhang H; Wei H; Luo X
    J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of oestrogen and progesterone receptors, and c-erbB-2 in carcinoma of the breast in Trinidadian women.
    Rao AV; Mohammed WA; Ragoonanan C; Omo-Igbinomwanhia NE
    West Indian Med J; 2002 Mar; 51(1):4-9. PubMed ID: 12089875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tie-1 tyrosine kinase is an independent prognostic indicator for invasive breast cancer.
    Tseng LM; Hsu CY; Wang HC; Liu JM; Chang HM; Lo SS; Wu CW; Lui WY; Chi CW
    Anticancer Res; 2001; 21(3C):2163-70. PubMed ID: 11501841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokeratin-positive cell dissemination in patients with in situ ductal carcinoma of the breast.
    Stelzmueller I; Hengster P; Obrist P; Duenser M; Margreiter R; Weiss H
    Int J Cancer; 2005 Mar; 114(1):161. PubMed ID: 15523701
    [No Abstract]   [Full Text] [Related]  

  • 39. Nuclear JAK2.
    Dawson MA; Bannister AJ; Saunders L; Wahab OA; Liu F; Nimer SD; Levine RL; Göttgens B; Kouzarides T; Green AR
    Blood; 2011 Dec; 118(26):6987-8. PubMed ID: 22194397
    [No Abstract]   [Full Text] [Related]  

  • 40. Fibroblast growth factor 23 and CKD prognosis.
    Tangri N; Levey AS
    Am J Kidney Dis; 2012 May; 59(5):607-10. PubMed ID: 22153824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.